期刊文献+

中国人HCV标本库的建立 被引量:12

Establishment of the serum specimen repository of HCV infected patients in China
下载PDF
导出
摘要 目的建立中国人HCV感染患者系列标本库。方法系列收集门诊及住院的HCV感染患者血液标本。所有血清标本进行基本的生化和病毒学检测。记录每一位患者的流行病学资料和临床与诊断检测结果。定期随访,不断扩充标本库。同时,对大部分HCVRNA阳性血清标本进行HCV基因型和亚型的确定。结果建立了中国人HCV标本库,收集605例HCV慢性感染患者的934份血清标本。完整记录了流行病学、临床及实验室资料,可提供研究所需的血清标本。对其中206份HCVRNA阳性感染者血清标本进行了基因型别的检测。序列与系谱分析结果显示1b87例(42.2%),2a26例(12.6%),3a32例(15.5%),3b30例(14.6%),6a31例(15.1%),未见1a和2b型。结论建立了中国人HCV标本库。为HCV的基础与临床研究奠定了良好的基础,也为其他疾病相关标本库的构建提供了参考。 Objective To establish the serum specimen repository of HCV infected patients in China. Methods Serum specimens of HCV infected in- and out-patients were continually collected since 2004. All spocimens were conducted for routine biochemistry and virology test. Special software used to manage the related data of specimens, including epidemiology information, clinical and laboratory data. Simultaneously, genotypes and subtypes of a part of HCV RNA positive serum specimens were determined by nucleotide sequencing and phylogenetic analysis. RT-PCR primers for genotyping were deduced from the relatively conserved region: core-envelope 1 ( C-E1 ) region. Amplicon fragment was 474 nt in length. Results HCV repository was established successfully. Up to now, 934 sectun specimens have collected from 605 HCV infected patients. Epidemiology information, clinical and laboratory test data of all patients were recorded in detail. Genotypes and subtypes of 206 HCV RNA positive serum specimens were determined, which contains five different subtypes of HCV: 1b (42.2%), 2a (12.6%), 3a (15.5%), 3b (14.6%), and 6a (15.1%), but not 1a or2b. Conclusion HCV repository is established, which will provide a basis for the HCV basic and clinical study.
出处 《免疫学杂志》 CAS CSCD 北大核心 2008年第5期568-571,共4页 Immunological Journal
基金 国家自然科学基金(30371663) 第三军医大学回国人员基金资助
关键词 丙型肝炎病毒 标本库 基因型 流行病学 Hepatitis C virus Specimen repository Genotype Epidemiology
  • 相关文献

参考文献12

  • 1Lyra AC, Fan X, Di Bisceglie AM. Molecular biology and clinical implication of hepatitis C virus [J]. Braz J Med Biol Res, 2004, 37 (5): 691- 695.
  • 2Hadziyannis S J, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose [ J]. Ann Intern Med 2004, 140 (5): 346 - 355.
  • 3Dale MN, Wang XH, Shruti HM, et al. Hepatitis C virus (HCV) core antigen assay to detect ongoing HCV infection in thai injection drug users [J]. J Clin Microbiol, 2004, 42 (4): 1 631- 1 636.
  • 4Hall TA. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT [J]. Nucl Acids Symp, 1999, 41: 95 - 98.
  • 5Kohli DK, Bachhawat AK. CLOURE: Clustal Output Reformatter, a program for refolvnatting ClustaIX/ClustaIW outputs for SNP analysis and molecular systematics [J]. Nucleic Acids Res,2003, 31 (13): 3 501 -3 502.
  • 6Anthony JC, Vlahov D, Celentano DD. Self-reported interview data for a study of HIV-1 infection among intravenous drug users: description of methods and preliminary evidence on validity [J]. J Drug Issues, 1991, 21 : 739- 757.
  • 7Yen T, Keeffe EB, Ahmed A. The Epidemiology of Hepatitis C Virus Infection [J]. J Clin Gastroenterol, 2003, 36 (1): 47 - 53.
  • 8Simmonds P. Viral heterogeneity of the hepatitis C vires[J]. J Hepatol, 1999, 31 (Suppl): 54-60.
  • 9Pawlotsky JM. Molecular diagnosis of viral hepatitis [J]. Gastroenterology, 2002, 122 (6): 1 554- 1 568.
  • 10丙型肝炎防治指南[J].临床肝胆病杂志,2004,20(4):197-203. 被引量:735

二级参考文献15

  • 1Camma C, Bruno S, Schepis F, et al. Retreatment with interferon plus ribavirin of chronic hepatitis C non- responders to interferon monotherapy: a meta- analysis of individual patient data[ J ]. Gut, 2002,51:864-869.
  • 2Papatheodoridis GV, Papadimitropoulos VC, Hsdziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus- reated cirrhosis: a meta- analysis[J] .Aliment Pnarmaool Ther, 2001,15:689- 698.
  • 3Kjaergard LL, Krogsgaard K, Gluud C. Interfern alfa with or without ribavirin for chronic hepatitis C: systematic review of randonmised trials[J].BMJ, 2001,323:1151 - 1155.
  • 4Alberti A, Benvegnu L. Management of hepatitis[J] .J Hepatol, 2003,38(Suppl1): S1014 - S1 18.
  • 5Poynard T, MdHutchison J, Davis GL, et al. Impact of interferon alfa - 2b and ribavirin on progression of liver fibrosiis in patients with chronic hepatitis C[J].Hepatology, 2000,32:1131 - 1137.
  • 6Booth JCL, O' Grady J, Neuberger J. Clinical guidelines on the mangement of hepatitis C[J]. Gut, 2001, 49(Suppl I ): il - i12.
  • 7Chander G, Sulkowski MS, Jenckes MW, et al. Treatment of chronic hepatitis C: a systemic review[J]. Hepatology, 2002, 36(5 Suppl 1 ):S135 - S144.
  • 8Di Ciomm no V, Russo P, Rava L, etal. Interferon alpha in the treatment of chronic hepatitis C in children: a mmeta- analysis[J] .J Viral Hepat,2003,10:210 - 214.
  • 9Fabrizi F, Dulai G, DixitV, et al. Meta- analysis: interfeorn for the treatment of chronic hepatitis C in dialysis patients[J] .Aliment Phamacol Ther, 2003,18:1071 - 1081.
  • 10National Institute of Health Consensus Development Conference Panel Statenent. Management of hepatitis C[J].Hepatology, 2002,36(5 Suppl 1):S3- S20.

共引文献734

同被引文献109

引证文献12

二级引证文献53

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部